Preparing the published article.
Wandercraft: Atalante X Rehabilitation and Personal Exoskeleton Boundaries
Review Wandercraft's Atalante X rehabilitation platform, device-specific US indications, its Australian distribution announcement, and the separate commercial timeline for personal exoskeletons.
Company and rehabilitation focus
Wandercraft develops self-balancing exoskeletons. Its Atalante product page positions Atalante X for rehabilitation institutions, with adjustable assistance and gait information for clinical teams. A hospital evaluating this platform should begin with its patient population, staffing and treatment environment. It should not treat the wider company portfolio as a single interchangeable medical device.
What Atalante X does
Atalante X is a powered lower-body system that supports ambulatory movement without requiring crutches. Hands-free operation does not remove professional supervision. Buyers should establish who selects eligible patients, adjusts the equipment, monitors sessions and responds to an interruption. Fitting time, transfer procedures and the required safety arrangement belong in a practical demonstration alongside walking tasks.
Specific United States indication
The FDA clearance letter and summary dated October 24, 2025 identify Wandercraft SAS and Atalante X. The indication covers adults able to tolerate standing, with hemiplegia following cerebrovascular accident, spinal cord injuries from C4 to L5, or multiple sclerosis. Use is in rehabilitation institutions under a trained operator. The document excludes sports and stair climbing and specifies use with a safety system.
Australian commercial route
On February 24, 2026, Wandercraft announced Australian availability, describing Atalante's ARTG Class IIa inclusion and NeuroNova Robotics as distributor and local sponsor. This is a supplier announcement about one market. Procurement teams should obtain the current Australian registration entry, local instructions and service agreement for the offered configuration before relying on an international product brochure.
Personal mobility is a separate product
An August 11, 2026 company announcement reported US FDA clearance for Eve, a personal exoskeleton, and scheduled its commercial launch for September 17, 2026. That launch remains future relative to this September 10 review. Eve's personal-use scope must not be substituted for Atalante X's institutional indication, and a launch announcement does not establish immediate delivery in every territory.
Clinical implementation and evidence
For a purchasing assessment, ask the clinical lead to define measurable objectives without promising an individual outcome. Useful operational measures include completed sessions, setup time, cancellations, staff involvement and reasons for stopping. Clinical effectiveness requires appraisal of appropriate studies and local practice requirements; manufacturer descriptions and regulatory clearance alone do not establish superiority over another rehabilitation approach.
Contact and contract planning
The Atalante page provides a demonstration route, while the Australian announcement identifies the regional distributor. Send the proposed country, institution, intended use and support expectations. Request installation requirements, operator training, preventive maintenance, software-version policy, data export terms and the process for field corrections. A quotation should name the contracting entity, importer where applicable, model and documentation language.
Questions for the buying team
Does the offered device's local indication match the intended patient cohort?
Which safety system, transfer equipment and staff competencies are required?
Who owns session records, and how can the institution retrieve them?
What installation, acceptance and service obligations are included?
Compare Medical & Rehabilitation Robots, Write a Robotics Buyer Brief, or prepare a Robotics RFQ.